Gemma L Saravanos1,2, Meru Sheel1,2, Nusrat Homaira3,4, Aditi Dey1,5, Edward Brown1,5, Han Wang1, Kristine Macartney1,2, Nicholas J Wood1,2. 1. National Centre for Research Immunisation and Surveillance, Sydney, NSW. 2. The University of Sydney Children's Hospital, Westmead Clinical School, Sydney, NSW. 3. School of Women's and Children's Health, University of New South Wales, Sydney, NSW. 4. Sydney Children's Hospital Randwick, Sydney, NSW. 5. Sydney Medical School, University of Sydney, Sydney, NSW.
Abstract
OBJECTIVE: To estimate rates of respiratory syncytial virus (RSV)-associated hospitalisation across the age spectrum, and to identify groups at particular risk of serious RSV-associated disease. DESIGN, SETTING AND PARTICIPANTS: Retrospective review of National Hospital Morbidity Database data for all RSV-associated hospitalisations in Australia, 2006-2015. MAIN OUTCOMES AND MEASURES: RSV-coded hospitalisation rates by age, sex, Indigenous status, jurisdiction, and seasonality (month and year); hospital length of stay; in-hospital deaths. RESULTS: During 2006-2015, there were 63 814 hospitalisations with an RSV-specific principal diagnostic code; 60 551 (94.9%) were of children under 5 years of age. The hospitalisation rate for children under 5 years was 418 per 100 000 population; for children under 6 months of age it was 2224 per 100 000 population; the highest rate was for infants aged 0-2 months (2778 per 100 000 population). RSV-coded hospitalisation rates were higher for adults aged 65 or more than for people aged 5-64 years (incidence rate ratio [IRR], 6.6; 95% CI, 6.2-7.1), and were also higher for Indigenous Australians than other Australians (IRR, 3.3; 95% CI, 3.2-3.5). A total of 138 in-hospital deaths were recorded, including 82 of adults aged 65 years or more (59%). CONCLUSIONS: Prevention strategies targeting infants, such as maternal or early infant vaccination, would probably have the greatest impact in reducing RSV disease rates. Further characterisation of RSV disease epidemiology, particularly in older adults and Indigenous Australians, is needed to inform health care strategies.
OBJECTIVE: To estimate rates of respiratory syncytial virus (RSV)-associated hospitalisation across the age spectrum, and to identify groups at particular risk of serious RSV-associated disease. DESIGN, SETTING AND PARTICIPANTS: Retrospective review of National Hospital Morbidity Database data for all RSV-associated hospitalisations in Australia, 2006-2015. MAIN OUTCOMES AND MEASURES: RSV-coded hospitalisation rates by age, sex, Indigenous status, jurisdiction, and seasonality (month and year); hospital length of stay; in-hospital deaths. RESULTS: During 2006-2015, there were 63 814 hospitalisations with an RSV-specific principal diagnostic code; 60 551 (94.9%) were of children under 5 years of age. The hospitalisation rate for children under 5 years was 418 per 100 000 population; for children under 6 months of age it was 2224 per 100 000 population; the highest rate was for infants aged 0-2 months (2778 per 100 000 population). RSV-coded hospitalisation rates were higher for adults aged 65 or more than for people aged 5-64 years (incidence rate ratio [IRR], 6.6; 95% CI, 6.2-7.1), and were also higher for Indigenous Australians than other Australians (IRR, 3.3; 95% CI, 3.2-3.5). A total of 138 in-hospital deaths were recorded, including 82 of adults aged 65 years or more (59%). CONCLUSIONS: Prevention strategies targeting infants, such as maternal or early infant vaccination, would probably have the greatest impact in reducing RSV disease rates. Further characterisation of RSV disease epidemiology, particularly in older adults and Indigenous Australians, is needed to inform health care strategies.
Authors: Mari D Takashima; Keith Grimwood; Peter D Sly; Stephen B Lambert; Keith J Chappell; Daniel Watterson; Robert S Ware Journal: Eur J Pediatr Date: 2021-02-25 Impact factor: 3.183
Authors: Allen L Nazareno; David J Muscatello; Robin M Turner; James G Wood; Hannah C Moore; Anthony T Newall Journal: Influenza Other Respir Viruses Date: 2022-06-30 Impact factor: 5.606
Authors: John-Sebastian Eden; Chisha Sikazwe; Ruopeng Xie; Yi-Mo Deng; Sheena G Sullivan; Alice Michie; Avram Levy; Elena Cutmore; Christopher C Blyth; Philip N Britton; Nigel Crawford; Xiaomin Dong; Dominic E Dwyer; Kimberly M Edwards; Bethany A Horsburgh; David Foley; Karina Kennedy; Cara Minney-Smith; David Speers; Rachel L Tulloch; Edward C Holmes; Vijaykrishna Dhanasekaran; David W Smith; Jen Kok; Ian G Barr Journal: Nat Commun Date: 2022-05-24 Impact factor: 17.694
Authors: Amanuel Tesfay Gebremedhin; Alexandra B Hogan; Christopher C Blyth; Kathryn Glass; Hannah C Moore Journal: Sci Rep Date: 2022-01-10 Impact factor: 4.379
Authors: Ainara Mira-Iglesias; Clarisse Demont; F Xavier López-Labrador; Beatriz Mengual-Chuliá; Javier García-Rubio; Mario Carballido-Fernández; Miguel Tortajada-Girbés; Juan Mollar-Maseres; Germán Schwarz-Chavarri; Joan Puig-Barberà; Javier Díez-Domingo Journal: Influenza Other Respir Viruses Date: 2021-11-24 Impact factor: 4.380
Authors: Daniel A Norman; Allen C Cheng; Kristine K Macartney; Hannah C Moore; Margie Danchin; Holly Seale; Jocelynne McRae; Julia E Clark; Helen S Marshall; Jim Buttery; Joshua R Francis; Nigel W Crawford; Christopher C Blyth Journal: Influenza Other Respir Viruses Date: 2021-11-16 Impact factor: 4.380
Authors: Li Wei Ang; Tze Minn Mak; Lin Cui; Yee Sin Leo; Vernon Jian Ming Lee; Raymond Tzer-Pin Lin Journal: Influenza Other Respir Viruses Date: 2020-02-24 Impact factor: 4.380
Authors: John McCauley; Ian G Barr; Terry Nolan; Theodore Tsai; Steven Rockman; Beverly Taylor Journal: Influenza Other Respir Viruses Date: 2021-10-03 Impact factor: 5.606